secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001193125-26-011748
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek sees Q4 rev $62M (+8% YoY); FY2025 rev ~$201M
---------------------------------------------------

- Preliminary Q4 2025 revenue of ~$62M, up 8% YoY and 19% QoQ.
- Full-year 2025 revenue estimated at ~$201M.
- CEO cites strong Services, Reagents and APAC instrument growth; EMEA returns to positive instrument sales.
- Company to present at JP Morgan Healthcare Conference on Jan 14, 2026.
- Full Q4 and FY results with 2026 guidance expected late February 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312526011748/0001193125-26-011748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312526011748/d41645d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-011748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer